Most common myths
This article debunks some of the most common myths associated with clinical trials, empowering you to make an informed decision about your lung cancer treatment journey.
Myth #1: Clinical trials are a last resort.
This is simply untrue. Clinical trials are not just for patients with exhausted treatment options. They play a crucial role in advancing medical knowledge and developing new, more effective treatments for lung cancer.
By participating in a clinical trial, you become a vital partner in the fight against this disease. The data collected from trials helps doctors refine existing treatment protocols and develop groundbreaking therapies.
Myth #2: Clinical trials are entirely experimental and unsafe.
While some trials do involve new and untested treatments, strict regulations are in place to ensure participant safety. Every clinical trial undergoes rigorous ethical review by a committee before it begins to ensure the trial will demonstrate a clear outcome. This committee ensures the trial design prioritises participant safety and well-being, with clear guidelines and protocols for monitoring potential risks.
Additionally, trials are typically conducted in three phases, with each phase building upon the findings of the previous one. This phased approach allows researchers to assess the safety and efficacy of the tested treatment progressively.
Myth #3: Clinical trials are only run by pharmaceutical companies.
While pharmaceutical companies do sponsor many clinical trials, there’s another category known as investigator-initiated clinical trials (IITs). These trials are initiated by independent researchers or medical institutions, often focusing on specific aspects of lung cancer treatment or innovative approaches not yet backed by large corporations. TOGA runs IIT in the hopes it will broaden treatment options. Some trials may explore new combinations or doses of existing treatments, supportive care practices, diagnostics, or new tests or procedures.
Myth #4: Trial results are never published.
Transparency and data sharing are becoming increasingly important in clinical research. Regulatory bodies now encourage the publication of all trial results, regardless of whether the findings are positive or negative. This ensures a complete picture of the tested treatment’s effectiveness and allows the scientific community to learn from both successes and failures.
Additionally, open-access journals and online registries like ANZCTR (Australian New Zealand Clinical Trials Registry) provide easy access to these published results.
Considering a Clinical Trial for Lung Cancer Treatment?
Now that you’ve explored these common myths, you might be wondering if a clinical trial is the right option for you. The decision ultimately depends on your individual circumstances, medical history, and treatment goals. Here are some additional factors to consider:
- The stage and type of your lung cancer
- Your current treatment options and their potential side effects
- The specific details of the clinical trial, including its design, eligibility criteria, and potential benefits and risks
Taking the Next Step
If you’re interested in learning more about clinical trials for lung cancer treatment, talk to your doctor. They can help you understand the available options and determine if a specific trial aligns with your unique needs. Additionally, resources like Cancer Australia and patient advocacy groups can provide valuable information and support throughout your decision-making process.
Remember, clinical trials are not a last resort; they are a chance to contribute to medical progress and potentially gain access to cutting-edge treatments. By demystifying the myths and empowering yourself with knowledge, you can unlock new possibilities on your path to optimal lung cancer treatment.
